FIELD: biotechnology.
SUBSTANCE: following is presented: an anti-CD22 antibody containing only heavy chains, a CAR-T molecule that binds to CD22, a multispecific antibody containing a first binding fragment that has a binding specificity for CD22 and a second binding fragment that has a binding affinity for an effector cell. Besides, polynucleotides encoding antibodies, a pharmaceutical composition containing such antibodies, and their use for the treatment of B-cell disorders characterized by CD22 expression are proposed.
EFFECT: invention makes it possible to obtain new antibodies with high affinity for HLA-G.
28 cl, 6 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS TARGETING DLL3 | 2020 |
|
RU2822366C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
